SFDA Clears Unique Non-Invasive, Radiation-Free Pulmonary Imaging System

Deep Breeze Ltd. VRIxp(TM) System for the Diagnosis of Respiratory
Conditions of the Lung
BEIJING--(Business Wire)--
Deep Breeze Ltd, the innovator in vibration response imaging
(VRI(TM)) technology, today announced that the State Food and Drug
Administration (SFDA) of the People's Republic of China has approved
the registration of the VRIxp(TM) device. VRIxp(TM) is a non-invasive,
radiation-free imaging system that creates dynamic functional imaging
of the lungs, it was approved by SFDA for assisting physicians to
diagnose and manage patients suffering from respiratory complaints.
This announcement marks Deep Breeze's official marketing approval of
the VRIxp(TM) device in China. The VRIxp(TM) system will be marketed
to specialists and physicians at hospitals, clinics and screening
centers.

The VRIxp(TM) device records lung vibrations from sensors applied
to a patient's back. The system then uses an algorithm to convert
these data into a dynamic functional image. Changes in tissue
composition and airflow affect the vibration intensity, dynamics and
distribution within the lung which are then reflected in the image
produced by the VRIxp(TM) system. This unique system has been
specifically designed for the management and diagnosis of lung
diseases such as COPD, lung cancer, pleural effusion, and airway
obstructions. In turn, better management can accelerate the
commencement of improve patient treatment.

"Ultimate Science Technology Co. Ltd (UST), as the official
representatives of Deep Breeze Ltd. in China, is proud to be part of
the introduction of the VRI(TM) technology into this important market.
Our first and foremost priority is to educate physicians on the unique
capabilities of the system and how they can benefit from it in their
daily practice in pulmonary medicine. We are committed on intensifying
and expanding our VRI(TM) market activities in China." said Mr. T. F.
Yu, Director and CEO of UST.

"The VRIxp(TM) system is a breakthrough in pulmonary medicine that
will allow us to improve patient care by providing a more detailed and
rapid diagnosis of lung conditions at the bedside without exposing the
patient to radiation. Physicians can now rapidly assess the outcome of
their therapy and effectively utilize it as a lung screening tool."
said Prof. Cai, Deputy Chairman of China Respiratory Association.

"The availability of the VRIxp(TM) system in China advances our
efforts to create a new clinical paradigm in which our technology will
be the standard application in a broad line of clinical applications,"
said Igal Kushnir, President and CEO of Deep Breeze Ltd. "It also
represents a significant development in the concerted push by Deep
Breeze Ltd. to build a global marketing and sales platform directed at
pulmonary medical care. Indeed, the potential for this medical
technology to diagnose, treat and effectively manage lung conditions
is unlimited."

About The VRIxp(TM) System:

The procedure takes only minutes in a physician's office and may
be performed repeatedly for continual monitoring. Results are
displayed immediately and can be stored in the built-in database for
future use. The radiation-free technology has been used in places such
as hospitals & clinics, ED and PFT labs. And surgical wards for
diagnosis and monitoring treatment procedures worldwide without any
single adverse event.

China:
Ultimate Science Technology Co. Ltd
T.F. Yu, +86 (10) 5169-7362
UST@ustus.com
or
Asia-Pacific:
Deep Breeze Ltd
Bob Grove, +852 2593 1530
Bob.Grove@deepbreeze.com

Copyright Business Wire 2008